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Despite the availability of population-based cancer survival data from the developed and developing countries, comparisons remain
very few. Such comparisons are important to assess the magnitude of survival discrepancies and to disentangle the impact of ethnic
background and health care access on cancer survival. Using the SEER 13 database and databases from the Manila and Rizal Cancer
Registries in the Philippines, a 5-year relative survival for 9 common cancers in 1998–2002 of Filipino-American cancer patients were
compared with both cancer patients from the Philippines, having the same ethnicity, and Caucasians in the United States, being
exposed to a similar societal environment and the same health care system. Survival estimates were much higher for the Filipino-
Americans than the Philippine resident population, with particularly large differences (more than 20–30% units) for cancers with
good prognosis if diagnosed and treated early (colorectal, breast and cervix), or those with expensive treatment regimens
(leukaemias). Filipino-Americans and Caucasians showed very similar survival for all cancer sites except stomach cancer (30.7 vs
23.2%) and leukaemias (37.8 vs 48.4%). The very large differences in the survival estimates of Filipino-Americans and the Philippine
resident population highlight the importance of the access to and utilisation of diagnostic and therapeutic facilities in developing
countries. Survival differences in stomach cancer and leukaemia between Filipino-Americans and Caucasians in the United States
most likely reflect biological factors rather than the differences in access to health care.
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Despite the availability of population-based cancer survival data
from the developed and developing countries (Sankaranarayanan
et al, 1998; Verdecchia et al, 2007), comparisons between
developing and developed countries remain very few (Gondos
et al, 2004, 2005; Coleman et al, 2008). Comparison of cancer
survival between countries or between ethnic population groups
within the same country may yield important information
regarding the magnitude of discrepancies in access to and
utilisation of health care between population groups. Furthermore,
they could also give insights on possible ethnic differences in
tumour biology.
Moreover, the survival experiences of similar ethnic populations
in developed and developing country settings have rarely been
compared, mostly because of the absence of data from the
developing countries. Very few population-based studies have
been conducted focusing on cancer survival in the Philippines and
of those that exists; most are outdated (Sankaranarayanan et al,
1998). Nevertheless, it has been shown that the survival estimates
of cancer patients in the Philippines were lower than those found
in developed countries (Sankaranarayanan et al, 1998). No earlier
study has included comparisons between the survival experience of
Filipinos in the Philippines and Filipinos residing in developed
countries. As various studies have suggested that access to health
care is a key factor affecting survival, the differences between
settings should be investigated.
The aim of this study was to assess the magnitude of survival
discrepancies and to disentangle the impact of ethnic background
and access to health care by comparing cancer survival in Filipino-
Americans to cancer patients from the Philippines, having the
same ethnicity, and to Caucasians in the United States, being
exposed to a similar societal environment and the same health care
system.
MATERIALS AND METHODS
For Filipino-Americans, data from the SEER 13 database
(Surveillance Epidemiology and End Results (SEER) Program)
for patients identified to be of Filipino origin, regardless of
birthplace, and diagnosed with the cancers of interest at the age of
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y15 years or above from 1 January 1993 to 31 December 2002 were
selected. Cancer patients who were identified by death certificates
only (DCO) and in situ cases were excluded. Data for a total of
13204 patients were used for the survival analysis.
For Caucasians, using the same inclusion and exclusion criteria,
612244 patients diagnosed with the cancers of interest between
1993 and 2002 whose race or ethnicities were coded as white,
including those coded as being of hispanic ethnicity, were included
in the analysis.
For cancer patients from the Philippines, data from the
Philippine Cancer Society-Manila Cancer Registry (PCS-MCR)
and the Department of Health-Rizal Cancer Registry (DOH-RCR)
were used. These registries cover the national capital region
(NCR), more commonly known as Metro Manila, with a
population of 9932560 (2000 census; NSCB, 2006).
For this survival study, subsamples of cancer patients who were
diagnosed at the age of 15 years or above between 1993 and 2002
were included in the analysis. From the lists of colorectal, breast,
ovarian and cervical cancer patients who met the inclusion criteria,
samples of 200 cases per site for each year studied were randomly
selected. For leukaemias, stomach, liver, lung and thyroid cancers,
samples of 100 patients per year per site were randomly selected.
Survival status was assessed through death certificate notifications
mentioning cancer as the cause of death, which were collected
from the Local Civil Registry Offices and matched with records
from the registry database. For those not identified as dead, active
follow-up by personal visits to the patients or their families in the
last known place of residence was used to confirm status. Of those
not matched to death certificates, complete 5-year survival was
obtained for 41.6% of the cases, whereas some survival informa-
tion was obtained for an additional 39%.
The original sample included 13000 patients. After all exclusions
because of invalid data (n¼1102, 8.5%) and lack of any follow-up
data (n¼1734, 13.3%), 10164 patients (78.2%) were left for the
survival analysis. Anonymised data sets were prepared and used in
the analysis.
The project proposal was approved by the Ethics Review Board
of the National Institutes of Health of the University of the
Philippines, Manila. The information obtained strictly conformed
to the code of conduct stipulated by the guidelines on
confidentiality for population-based cancer registries (Interna-
tional Association of Cancer Registries and International Agency
for Research on Cancer, 2004). Informed consent was obtained
from patients who were followed-up at the places of residence.
Data analysis
Traditionally, cohort-based analysis, which includes the conven-
tional life table (actuarial) method or the Kaplan–Meier method
(Cutler and Ederer, 1958; Kaplan and Meier, 1958) has mostly been
used to derive survival estimates. Here, period analysis, a new
method of survival analysis introduced by Brenner and Gefeller in
1996 was used (Brenner and Gefeller, 1996). It has been shown that
period analysis provides more up-to-date estimates of survival that
closely predicts survival later observed for patients diagnosed in
the respective period (Brenner et al, 2002; Brenner and Hakulinen,
2002a,b; Ta ¨lback et al, 2004; Ellison, 2006).
According to common practice in population-based cancer
survival analysis, relative rather than absolute survival is reported.
Relative survival reflects the survival experience of cancer patients
in the absence of competing causes of death (Ederer et al, 1961;
Henson and Ries, 1995). It is calculated as the ratio of the observed
survival of the cancer patients and the expected survival of a group
of people with the same age and sex distribution from the general
population. For all groups, expected survival was derived from life
tables for the year 2000 using the so-called Ederer II method
(Ederer and Heise, 1959). The life table for the US population was
obtained from the US National Center for Health Statistics
(Arias, 2002). Because of the absence of life tables for other races
for 2000, the life table for whites was used for both SEER
populations. The life table for the Philippine resident population
was derived from the projected population estimate and the actual
mortality data for this area, which were obtained from the
Philippine National Statistics Office (NSO).
To compare the survival estimates between the different cancer
populations, age adjustment is warranted. For this purpose, age-
specific period survival estimates for age groups 15–44,
45–54, 55–64, 65–74 and 75 years and above were obtained from
the Philippine resident, the Filipino-American and from the
Caucasian populations. For each of the cancer populations, the
age-specific estimates were weighted and then summed. Weights
used were taken from the World Standard Cancer Patient Population
(WSCPP; Sankaranarayanan et al, 1998), with the exception of
thyroid cancer. In the absence of an appropriate standard population
for thyroid cancer in WSCPP, the International Cancer Survival
Standards suggested by Corazziari et al (2004) were used.
The differences between relative survival estimates for the
different cancer populations were tested for statistical significance
using a novel modelling approach for period analysis (Brenner and
Hakulinen, 2006). First, age-specific numbers of patients at risk
and of deaths by year of follow-up were calculated separately for
each group. Then, Poisson regression models were fitted, in which
the numbers of deaths were modelled as a function of the
population group (Philippine residents or Filipino-Americans or
Caucasians), year of follow-up (1, 2, 3, 4, 5 – entered as a
categorical variable) and age-group (15–44, 45–54, 55–64, 65–74,
75þ – entered as a categorical variable), using the logarithm of the
person-years at risk as offset, and accounting for late entries and
withdrawals as half persons. This approach allowed testing for
significance of differences in relative survival after adjustment for
age, based on P-values for the population parameter estimate. A
significance level of a¼0.05 (two-sided testing) was employed.
All analyses were performed with the SAS Statistical Analysis
Software, using special macros for standard and modelled period
survival analysis as described previously (Brenner et al, 2004b;
Brenner and Hakulinen, 2006).
RESULTS
Table 1 shows the numbers of cases, the mean age at diagnosis and
the proportions of female and histologically verified cases for the
Philippine resident, Filipino-American and Caucasian patients. For
most forms of cancer, the US Caucasian patients were on average
about 10 or more years older than Philippine resident patients,
with Filipino-American patients having intermediate mean ages.
The age difference was most pronounced for leukaemia. In
contrast, mean ages were rather similar across groups for patients
with cervical and thyroid cancers. For most cancers, the
proportions of male and female cases were similar between
the three groups, with the exception of stomach cancer where the
proportion of female cases was higher in the Philippines, and in
liver and lung cancers where the proportion of female cases was
higher among Caucasian patients. In all three populations, the vast
majority of cancers were histologically verified. However, the
proportion of histologically verified cases was markedly lower in
the Philippines than in the other populations for cancers of the
stomach, liver and lung.
The age-adjusted 5-year relative survival estimates for the 1998–
2002 period are shown in Table 2. In all three populations, patients
with thyroid cancer had the highest 5-year relative survival (82.4,
91.3 and 92.3% for the Philippine resident, Filipino-American and
Caucasian patients, respectively). Liver cancer showed the lowest
survival among the Filipino-Americans (11.7%) and Caucasian
patients (12.3%), whereas survival was lowest for patients with
leukaemia (5.2%) in the Philippines.
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yComparing Filipino-American and the Philippine resident
patients, all survival estimates for Filipino-American patients were
higher. The differences in survival estimates ranged from 3.2%
units for liver cancer to 32.6% units for leukaemias. With the
exception of stomach and liver cancer, all of the differences were
statistically significant.
Between Filipino-Americans and Caucasian patients, survival
differences were mostly small and statistically not significant.
However, survival was substantially and significantly higher
among Filipino-American than among Caucasian patients with
stomach cancer (30.7 vs 23.2%, P¼0.04), whereas the opposite was
true for patients with leukaemia (37.8 vs 48.4%, Po0.0001).
Comparing the Filipino-American and Caucasian stomach cancer
patients, more Filipino-Americans were diagnosed with non-cardia
gastric cancer (82.2 vs 63.2%). For leukaemias, more Filipino-
Americans were diagnosed with acute myeloid leukaemia
(AML; 33.2 vs 19.4%), whereas more Caucasians were diagnosed
with chronic lymphocytic leukaemia (CLL; 40.2 vs 9.8%).
DISCUSSION
This study shows one of the few comparisons of cancer survival
between developed and developing country settings. To our know-
ledge, this is the first comprehensive comparison of cancer survival
of Filipino-American cancer patients with both cancer patients from
the Philippines, who have the same ethnicity, and Caucasians in
the United States, who share a similar societal environment and the
same health care system. Through the application of period analysis,
up-to-date survival estimates could be obtained.
When compared with the Filipino-American patients, the
survival estimates for the Philippine resident patients are generally
much lower. Survival estimates are similar only for cancer sites for
which the chances of cure are low even in developed countries
(liver, lung and stomach cancers). By contrast, large differences are
seen for cancers associated with a moderate-to-good prognosis if
diagnosed and adequately treated early (colorectal, breast and
cervical cancers), suggesting that the stage at diagnosis and quality
of treatment are important determinants of survival. On the basis
of the registry data, among the Filipino-American breast cancer
patients with staging information, 55.8% were diagnosed to have
tumours at T0-1 stages, whereas this proportion was only 11.8% in
the Philippine resident population. For cervical cancer, 55.6 and
23.9% of cases were identified to have stage I (International
Federation of Gynecology and Obstetrics (FIGO)) cancers among
Filipino-American and Philippine resident patients, respectively.
Survival estimates are also strongly divergent for cancers for
which effective but very expensive treatment regimens are
available such as leukaemias. This pattern reflects low access of
the Philippine population to such therapeutic regimens. However,
for ovarian cancer, in spite of the high cost of therapy, survival for
the Filipino-Americans was only moderately higher than for
patients in the Philippines. One possible explanation could be that
the patients in the Philippines were less often diagnosed with clear
cell carcinoma (6.1 vs 10.2%), which is associated with poorer
prognosis (Chan et al, 2008).
Table 1 Description of cancer patients included in the period survival analysis, Philippine residents and Filipino-Americans and Caucasians from the US
SEER, 1993–2002

















Stomach 792 60.2 (14.2) 46.0 82.1 516 67.8 (13.9) 39.2 99.0 19432 69.3 (13.9) 37.8 98.5
Colorectal 1635 58.8 (14.7) 48.0 92.0 2598 65.6 (13.9) 43.3 98.8 139479 70.4 (12.9) 49.5 98.7
Liver 772 56.4 (14.8) 25.1 49.2 570 64.2 (14.2) 25.4 78.4 10078 66.6 (13.3) 33.6 78.8
Lung 840 59.9 (11.7) 26.9 79.6 2932 67.7 (11.4) 29.8 95.6 156286 68.7 (10.9) 45.3 93.6
Leukaemia 718 43.5 (19.9) 49.7 98.5 483 59.3 (18.8) 44.3 98.1 29812 64.9 (17.4) 41.8 97.0
Breast 1615 51.4 (12.7) 100.0 95.0 4203 55.5 (12.4) 100.0 99.9 202928 62.4 (14.4) 100.0 99.4
Cervix 1580 49.8 (12.3) 100.0 98.1 479 53.0 (13.9) 100.0 99.6 13285 49.2 (15.8) 100.0 99.6
Ovary 1475 48.2 (15.2) 100.0 90.5 448 54.1 (14.6) 100.0 98.0 21052 62.5 (15.4) 100.0 96.5
Thyroid 737 45.8 (15.9) 81.8 96.1 975 49.1 (16.0) 79.4 99.9 19892 47.4 (16.3) 74.7 99.9
s.d.¼standard deviation.
aHistologically verified cases.
Table 2 A 5-year relative survival (%) of cancer patients adjusted to the World Standard Cancer Patient Population, Philippine residents and Filipino-
Americans and whites from the US SEER, 1998–2002
(1) Philippine residents Between (1) and (2) (2) Filipino-Americans Between (2) and (3) (3) Caucasians
Site Period estimate s.e. Difference P-value Period estimate s.e. Difference P-value Period estimate s.e.
Stomach 27.3 4.9 3.4 0.09 30.7 3.6  7.5 0.04 23.2 0.5
Colorectal 40.2 4.4 22.0 o0.0001 62.3 1.9 1.8 0.72 64.0 0.2
Liver 8.5 1.9 3.2 0.06 11.7 2.4 0.6 0.89 12.3 0.7
Lung 12.0 3.7 6.0 o0.0001 17.9 1.2  0.7 0.06 17.3 0.2
Leukaemia 5.2 1.5 32.6 o0.0001 37.8 3.8 10.6 o0.0001 48.4 0.5
Breast 58.6 4.1 31.0 o0.0001 89.6 1.2  1.3 0.51 88.3 0.1
Cervix 45.4 3.7 21.7 o0.0001 67.2 3.3 0.2 0.68 67.4 0.7
Ovary 49.5 4.8 6.6 0.03 56.1 3.4  5.9 0.35 50.2 0.5
Thyroid
a 82.4 5.7 8.9 0.00003 91.3 2.4 1.0 0.71 92.3 0.5
s.d.¼standard error.
aAdjusted to the International Cancer Survival Standards suggested by Corazziari et al (2004).
Cancer survival in developed and developing countries
MT Redaniel et al
860












yThe differences between the Filipino resident population and
Filipino-Americans suggest continued inadequacy of access to or
utilisation of diagnostic and therapeutic procedures in the
Philippines. Although diagnostic and treatment facilities are
available, access for a majority of cancer patients is still a problem.
For most part, these services are costly for the average Filipino as
these are mainly offered by private hospitals and clinics.
Government facilities offer subsidised services, but these are
limited, with public hospitals accounting for only 25% of the total
number of hospitals in the NCR (NSCB, 2006). Moreover, most
Filipino cancer patients seek medical advice only when sympto-
matic or in the advanced stages (Ngelangel and Wang, 2001). In
spite of the high level of education of the population in the NCR,
there seems to persist a lack of trust in one’s chances to be cured
(Pisani et al, 2006). Regardless of health information campaigns, a
diagnosis of cancer is still viewed by many as life-threatening.
Between the Filipino-American and Caucasian patients, survival
is comparable for most cancers. These results are consistent with
those of earlier studies mostly focusing on single forms of cancers
(Flood et al, 2000; Pineda et al, 2001; Lin et al, 2002; McGuire et al,
2002; Hashibe et al, 2003; Pagano et al, 2003; Chien et al, 2005;
Gomez et al, 2007; Sun et al, 2007). Existing differences probably
lie more in biological factors than health care-related factors.
The difference in the survival estimates for stomach cancer could
be explained by the higher proportion of non-cardia gastric cancer
cases in Filipino-American patients than in Caucasian patients.
Non-cardia gastric cancer is strongly associated with Helicobacter
pylori infection (Brenner et al, 2004a) and higher relapse-free and
overall survival (Verdecchia et al, 2004). For leukaemias, the
survival advantage of Caucasian patients may reflect the higher
proportion of CLL, which is associated with good survival
(Xie et al, 2003; Brenner et al, 2008) and the lower proportion of
AML, which is associated with poor survival (Xie et al, 2003; Pulte
et al, 2008). The survival estimates of Filipino-Americans were
higher than those of Caucasians for ovarian cancer, although the
difference was not statistically significant. Although more Filipino-
Americans were diagnosed with clear cell carcinomas (10.0 vs
4.9%), Filipino-Americans were younger, and a higher proportion
was diagnosed at an earlier stage (FIGO stage I, 36.0 vs 24.5%).
For the Filipino-American population, one factor that could
have an effect on survival is acculturation. It can be argued that the
degree of acculturation of immigrants might have an impact on
survival, with those more acculturated having better access to and
greater utilisation of health care facilities, particularly those
concerning the early detection, diagnosis and quality treatment
of certain types of cancer. In two earlier studies, foreign-born
Asian-Americans had lower survival than those born in the United
States (Choe et al, 2005; Chuang et al, 2006). However,
acculturation did not have an effect on cancer survival in a study
focusing on Asian-American patient groups, including Filipino-
Americans (Pineda et al, 2001). In our study population, almost
70% of the Filipino-American patients were born in the
Philippines, and the comparably high survival rates of this ethnic
group, compared with the Caucasian residents, suggest a rapid and
profound acculturation.
Some limitations should be considered in the interpretation of
these survival estimates. Population-based survival figures are
influenced by a variety of factors, including those related to cancer
services, such as organisation, training and skills of health care
professionals, application of guidelines and diagnostic and
treatment facilities, and clinical factors, such as tumour stage
and biology (Verdecchia et al, 2007). With the use of age
standardisation and the relative survival methodology, the impact
of age differences should be minimised. Unfortunately, informa-
tion on stage distribution was incomplete and not fully comparable
for most cancers in both Philippine registries. The same applies to
the information on various types of therapy and socioeconomic
indices, which limits the possibilities to explore the issues
underlying the survival differences in more detail.
The differences in cancer survival between Filipino-American
and Philippine resident patients confirm the importance of access
to diagnostic and therapeutic facilities.
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